BURLINGTON, ON, March 1,
2023 /CNW/ - EcoSynthetix Inc. (TSX: ECO)
("EcoSynthetix" or the "Company"), a renewable
chemicals company that produces a portfolio of commercially proven
bio-based products, today announced its financial and operational
results for the three months (Q4 2022) and twelve months (FY 2022)
ended December 31, 2022. Financial
references are in U.S. dollars unless otherwise indicated.
Highlights
(Comparison periods in each case are the
three months ended December 31,
2021)
- Recorded net sales of $5.6
million in Q4 2022, up 15%, due to a higher average selling
price which impacted sales by 23%, partly offset by lower volumes
of 8%
- Gross profit of $0.9 million in
Q4 2022, down 9%, due to lower volumes and higher manufacturing
costs which offset higher average selling price
- Recorded an Adjusted EBITDA1 loss of $0.3 million in Q4 2022, unchanged from the prior
period
- Purchased and cancelled 265,200 common shares in Q4 2022 under
the normal course issuer bid for total consideration of
$0.8 million
- Maintained a strong balance sheet with cash and term deposits
of $36.0 million as at December 31, 2022
- Received the Platinum designation for the second consecutive
year from EcoVadis, a globally recognized agency for business
sustainability ratings of supply chains, by scoring within the top
1% of the 90,000 companies rated
- Subsequent to the end of the quarter, a backward integrated
producer of particleboard for a leading international retailer,
identified the use of bio-based glues as a key enabler to achieving
their climate targets and committed to a meaningful step in its
implementation of DuraBind™ resin
- Subsequent to the end of the quarter, the Company announced
improvements to its asset bases in North
America and Europe,
including internalizing 30 million pounds of annualized nameplate
manufacturing capacity at its Centre of Innovation in Burlington, Ontario
"Based on our progress in 2022, we are more confident in the
future opportunities we are working toward with our biopolymer
platform that addresses multi-billion markets," said Jeff MacDonald, CEO of EcoSynthetix. "The
announcement from our key strategic wood composites account
committing to a step forward in their implementation of DuraBind™
gives us conviction that we will be successful in the long-term
opportunity with them and their supply chain partners. Our work
with Dow, and their award-winning MaizeCare™ formulations, give us
conviction we're doing the right things with the right partner in
the personal care market. The three new wins with our strength aids
in the tissue and paperboard markets tell us we're working on the
right new growth opportunities. With the macro economic challenges
across many of our end markets, we anticipate softness in Q1 sales
including continued demand deterioration in the legacy graphic
paper end market and customer destocking, however we are confident
we are executing the right commercial strategy for the success of
the business with a multiple shots on goal approach."
Mr. MacDonald continued, "Our key priorities for 2023 are
growing volumes at existing production lines that use our
biopolymers, expanding to new lines with existing accounts and
winning new accounts. Our bio-based binders offer a unique value
proposition. We deliver value and performance as an alternative to
traditional petroleum-based binders. We can also help manufacturers
and retailers reduce their carbon footprint and emissions and
achieve their climate targets with our sustainable biopolymers. We
have the platform, team and capital resources to deliver higher
growth as the market continues to move toward more sustainable
solutions in their supply chains."
Financial Summary
Net Sales
Net sales were $5.6 million and
$19.0 million for Q4 2022 and FY
2022, respectively, compared to $4.9
million and $18.2 million for
the corresponding periods in 2021. The 15% increase in the
quarterly period was due to a higher average selling price which
impacted sales by $1.1 million, or
23%, which was partly offset by lower volumes which impacted sales
by $0.4 million or 8%. The 5%
increase in FY 2022 was due to a higher average selling price which
impacted sales by $5.0 million, or
28%, partly offset by lower volumes which impacted sales by
$4.2 million, or 23%. The higher
average selling price during Q4 2022 and FY 2022, was due to the
offsetting of significant inflationary pressures with price
increases and the volume decreases during Q4 2022 and FY 2022 were
due to a stepdown in demand for most products and regions when
compared to the prior period.
Gross Profit
Gross profit was $0.9 million and
$4.2 million for Q4 2022 and FY 2022,
respectively, compared to $1.0
million and $4.0 million for
the corresponding periods in 2021. During both periods, a higher
average selling price was offset by decreases in sales volumes and
rising costs of manufacturing.
Gross profit as a percentage of sales was 16.4% and 21.8% for Q4
2022 and FY 2022, respectively, compared to 20.7% and 21.9% for the
corresponding periods in 2021. Gross profit as a percentage of
sales adjusted for manufacturing depreciation was 21.4% and 25.5%
for Q4 2022 and FY 2022, respectively, compared to 24.8% and 26.2%
for the corresponding periods in 2021. The changes in both metrics
during the quarterly and annual periods were primarily due to
higher manufacturing costs partially offset by a higher average
selling price.
Selling, General and Administrative
Selling, general and administrative expenses (SG&A) were
$1.3 million and $5.1 million for Q4 2022 and FY 2022,
respectively, compared to $1.5
million and $5.4 million for
the corresponding periods in 2021. The improvement in the quarterly
period was primarily due to lower salaries and benefits of
$0.1 million and lower share-based
compensation of $0.1 million.
The improvement in the annual period was primarily due to
lower salaries and benefits of $0.6
million, partially offset by $0.1
million lower payments received under the Canadian Emergency
Wage Subsidy, $0.2 million in higher
discretionary spend and a $0.1
million change in foreign exchange gains and losses.
Research and Development
Research and development (R&D) costs were $0.6 million and $1.9
million for Q4 2022 and FY 2022, respectively, which were in
line with $0.5 million and
$1.8 million in the corresponding
periods in 2021. R&D expense as a percentage of sales was 10%
for each of Q4 2022 and FY 2022, respectively, unchanged from the
corresponding periods in 2021. The Company's R&D efforts
continue to focus on further enhancing value for our existing
products and expanding addressable opportunities.
Adjusted EBITDA1
Adjusted EBITDA loss was $0.3
million and $0.9 million for
Q4 2022 and YTD 2022, respectively, which was in line with the
corresponding periods in 2021.
Net Loss
Net loss was $0.7 million, or
$0.01 per common share, and
$2.4 million, or $0.04 per common share, for Q4 2022 and FY 2022,
respectively, compared to $0.9
million, or $0.02 per common
share, and $3.2 million, or
$0.06 per common share, for the
corresponding periods in 2021. The improvement in the quarterly
period was due to a higher interest income of $0.2 million. The improvement in the annual
period was primarily due to lower loss from operations of
$0.3 million and higher interest
income of $0.5 million. The higher
interest income in both periods was due to an increase in interest
rates on cash and term deposits.
Liquidity
Cash on hand and term deposits were $36.0
million as at December 31,
2022, compared to $42.2
million as at December 31,
2021. The $6.2 million change
was primarily due to an increase in inventory of $3.1 million, an increase in accounts receivable
of $1.0 million, and $2.2 million of cash used to purchase shares
through the NCIB. The Company purchased and cancelled 265,200 and
626,400 common shares under the normal course issuer bid during the
Q4 2022 and FY 2022 periods, respectively, for consideration of
$0.8 million and $2.2 million.
Notice of Conference Call
EcoSynthetix will host a conference call Thursday, March 2, 2023, at 8:30 AM ET to discuss its financial results.
Jeff MacDonald, CEO, and
Robert Haire, CFO, will co-chair the
call. All interested parties can instantly join the call by phone,
by following the URL https://bit.ly/3Y7dYBu to easily register and
be connected into the conference call automatically or the
conventional method by dialling (416) 764-8659 or (888) 664-6392
with the conference identification of 52875682. Please dial in 15
minutes prior to the call to secure a line. A live audio webcast of
the conference call will also be available at www.ecosynthetix.com
or https://app.webinar.net/eo6lpx0pZ5q. The presentation will be
accompanied by slides, which will be available via the webcast link
and the Company's website. Please connect at least 15 minutes prior
to the conference call to ensure adequate time for any software
download that may be required to join the webcast.
1Non-IFRS Financial Measures
This press release makes reference to certain non-IFRS measures.
These non-IFRS measures are not recognized measures under IFRS, do
not have a standardized meaning prescribed by IFRS and are
therefore unlikely to be comparable to similar measures presented
by other companies. Rather, these measures are provided as
additional information to complement those IFRS measures by
providing a further understanding of results of operations of
EcoSynthetix from management's perspective. Accordingly, they
should not be considered in isolation nor as a substitute for
analysis of the financial information of EcoSynthetix reported
under IFRS. The Company uses non-IFRS measures such as Adjusted
EBITDA to provide investors with a supplemental measure of
operating performance and thus highlight trends in its core
business that may not otherwise be apparent when relying solely on
IFRS financial measures. Management also believes that securities
analysts, investors and other interested parties frequently use
non-IFRS measures in the evaluation of issuers. Management also
uses non-IFRS measures in order to facilitate operating performance
comparisons from period to period, prepare annual operating budgets
and assess the Company's ability to meet its capital expenditure
and working capital requirements.
Adjusted EBITDA is not a measure recognized under IFRS and does
not have a standardized meaning prescribed by IFRS. See "IFRS and
Non-IFRS Measures." The Company presents Adjusted EBITDA because
the Company believes it facilitates investors' use of operating
performance comparisons from period to period and company to
company by backing out potential differences caused by variations
in capital structures (affecting relative interest expense), the
book amortization of intangibles (affecting relative amortization
expense) and the age and book value of property and equipment
(affecting relative depreciation expense). The Company also
presents Adjusted EBITDA because it believes it is frequently used
by securities analysts, investors and other interested parties as a
measure of financial performance. Adjusted EBITDA as presented
herein are not recognized measures under IFRS and should not be
considered as an alternative to operating income or net income as
measures of operating results or an alternative to cash flows as
measures of liquidity. Adjusted EBITDA is defined as consolidated
net income (loss) before net interest expense, income taxes,
depreciation, amortization, other non-cash expenses and charges
deducted in determining consolidated net income (loss).
The following table reconciles net loss to Adjusted EBITDA loss
for the three months and twelve months ended December 31, 2022 and December 31, 2021:
|
Three months
ended
December 31, 2022
|
Three months
ended
December 31, 2021
|
Twelve months
ended
December 31, 2022
|
Twelve months
ended
December 31, 2021
|
Net Loss
|
(650,674)
|
(936,867)
|
(2,375,244)
|
(3,179,740)
|
Depreciation
|
396,293
|
324,387
|
1,137,465
|
1,380,832
|
Share-based
Compensation
|
174,156
|
289,998
|
883,457
|
937,260
|
Interest
Income
|
(256,083)
|
(10,499)
|
(528,037)
|
(62,426)
|
Adjusted EBITDA
loss
|
(336,308)
|
(332,981)
|
(882,359)
|
(924,074)
|
About EcoSynthetix Inc. (www.ecosynthetix.com)
EcoSynthetix
offers a range of sustainable engineered biopolymers
that allow customers to reduce their use of harmful
materials, such as formaldehyde and styrene-based chemicals. The
Company's flagship products, DuraBind™,
Surflock™, Bioform™, and
EcoSphere®, are used to manufacture wood composites, personal
care, paper, tissue and packaging products, and enable performance
improvements, economic benefits and carbon footprint reduction. The
Company is publicly traded on the Toronto Stock Exchange
(T:ECO).
Forward-Looking Statements
Certain statements in this Press Release constitute
"forward-looking" statements that involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance, objectives or achievements of the Company, or industry
results, to be materially different from any future results,
performance, objectives or achievements expressed or implied by
such forward looking statements. The forward-looking statements in
this Press Release include, but are not limited to, statements
regarding the Company's plans to execute its commercial strategy,
deliver meaningful growth across all three product categories,
convert high-value strategic prospects into customers, and other
statements regarding the Company's plans and expectations in 2023.
These statements reflect our current views regarding future events
and operating performance and are based on information currently
available to us, and speak only as of the date of this Press
Release. These forward-looking statements involve a number of
risks, uncertainties and assumptions and should not be read as
guarantees of future performance or results, and will not
necessarily be accurate indications of whether or not such
performance or results will be achieved. Those assumptions and
risks include, but are not limited to, the Company's ability to
successfully allocate capital as needed and to develop new
products, as well as the fact that our results of operations and
business outlook are subject to significant risk, volatility and
uncertainty. Many factors could cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements that may be expressed
or implied by such forward-looking statements, including the
factors identified in the "Risk Factors" section of the Company's
Annual Information Form dated February 28,
2023. Should one or more of these risks or uncertainties
materialize, or should assumptions underlying the forward-looking
statements prove incorrect, actual results may vary materially from
those described in this Press Release as intended, planned,
anticipated, believed, estimated or expected. Unless required by
applicable securities law, we do not intend and do not assume any
obligation to update these forward-looking statements.
EcoSynthetix
Inc.
|
|
|
Consolidated Balance
Sheets
|
|
|
(expressed in US
dollars)
|
|
|
|
|
|
|
|
|
|
December 31,
2022
|
December 31,
2021
|
Assets
|
|
|
|
|
|
Current
assets
|
|
|
Cash
|
4,808,606
|
42,226,816
|
Term
deposits
|
21,054,812
|
-
|
Accounts
receivable
|
2,912,000
|
1,912,390
|
Inventory
|
5,317,367
|
2,073,800
|
Government grants
receivable
|
18,386
|
6,676
|
Prepaid
expenses
|
85,131
|
91,930
|
|
34,196,302
|
46,311,612
|
|
|
|
Non-current
assets
|
|
|
Term
deposits
|
10,138,542
|
-
|
Property, plant and
equipment
|
3,859,413
|
4,670,089
|
|
13,997,955
|
4,670,089
|
|
|
|
Total
assets
|
48,194,257
|
50,981,701
|
|
|
|
|
|
|
Liabilities
|
|
|
|
|
|
Current
liabilities
|
|
|
Trade accounts payables
and accrued liabilities
|
2,595,353
|
2,363,630
|
|
|
|
Non-current
liabilities
|
|
|
Lease
liability
|
543,639
|
820,045
|
|
|
|
Total
liabilities
|
3,138,992
|
3,183,675
|
Shareholders'
Equity
|
|
|
Common
shares
|
491,700,059
|
492,297,041
|
Contributed
surplus
|
10,081,456
|
9,851,991
|
Accumulated
deficit
|
(456,726,250)
|
(454,351,006)
|
Total shareholders'
equity
|
45,055,265
|
47,798,026
|
|
|
|
Total liabilities
and shareholders' equity
|
48,194,257
|
50,981,701
|
EcoSynthetix
Inc.
|
|
|
|
|
|
Consolidated
Statements of Operations and Comprehensive Loss
|
|
|
For the three and
twelve months ended December 31, 2022 and 2021
|
|
(expressed in US
dollars)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months
ended December 31,
|
|
Twelve months
ended December 31,
|
|
2022
|
2021
|
|
2022
|
2021
|
|
|
|
|
|
|
Net
sales
|
5,609,083
|
4,885,420
|
|
19,034,526
|
18,161,891
|
|
|
|
|
|
|
Cost of
sales
|
4,687,363
|
3,872,001
|
|
14,880,420
|
14,190,221
|
|
|
|
|
|
|
Gross profit on
sales
|
921,720
|
1,013,419
|
|
4,154,106
|
3,971,670
|
|
|
|
|
|
|
Expenses
|
|
|
|
|
|
Selling, general and
administrative
|
1,272,605
|
1,494,155
|
|
5,135,247
|
5,382,396
|
Research and
development
|
555,872
|
466,630
|
|
1,922,140
|
1,831,440
|
|
1,828,477
|
1,960,785
|
|
7,057,387
|
7,213,836
|
|
|
|
|
|
|
Loss from
operations
|
(906,757)
|
(947,366)
|
|
(2,903,281)
|
(3,242,166)
|
|
|
|
|
|
|
Net interest
income
|
256,083
|
10,499
|
|
528,037
|
62,426
|
Net loss and
comprehensive loss
|
(650,674)
|
(936,867)
|
|
(2,375,244)
|
(3,179,740)
|
|
|
|
|
|
|
Basic and diluted
loss per common share
|
(0.01)
|
(0.02)
|
|
(0.04)
|
(0.06)
|
Weighted average
number of common shares outstanding
|
58,994,283
|
57,871,822
|
|
58,898,673
|
57,410,885
|
EcoSynthetix
Inc.
|
|
|
|
|
|
Consolidated
Statements of Cash Flows
|
|
|
|
|
|
For the three and
twelve months ended December 31, 2022 and 2021
|
|
|
|
|
|
(expressed in US
dollars)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months
ended December 31,
|
|
Twelve months
ended December 31,
|
|
2022
|
2021
|
|
2022
|
2021
|
Cash provided by
(used in)
|
|
|
|
|
|
|
|
|
|
|
|
Operating
activities
|
|
|
|
|
|
Net loss and
comprehensive loss
|
(650,674)
|
(936,867)
|
|
(2,375,244)
|
(3,179,740)
|
Items not affecting
cash
|
|
|
|
|
|
Depreciation
|
396,293
|
324,387
|
|
1,137,465
|
1,380,832
|
Share-based
compensation
|
174,156
|
289,998
|
|
883,457
|
937,260
|
Other
|
(283,370)
|
(20,168)
|
|
(205,838)
|
60,361
|
Changes in non-cash
working capital
|
|
|
|
|
|
Accounts
receivable
|
(377,870)
|
184,549
|
|
(999,610)
|
(272,807)
|
Inventory
|
(562,763)
|
466,681
|
|
(3,148,809)
|
(31,615)
|
Government grants
receivable
|
6,057
|
15,807
|
|
(11,710)
|
115,542
|
Prepaid expenses
|
51,387
|
40,162
|
|
6,799
|
(22,297)
|
Trade accounts payables and
accrued liabilities
|
152,616
|
(75,633)
|
|
130,577
|
1,141,956
|
Interest on term
deposits
|
|
|
|
|
|
Interest received on term deposits
|
77,069
|
-
|
|
77,069
|
358,740
|
Accrued interest on term deposits
|
(207,550)
|
-
|
|
(390,114)
|
(14,165)
|
|
(1,224,649)
|
288,916
|
|
(4,895,958)
|
474,067
|
|
|
|
|
|
|
Investing
activities
|
|
|
|
|
|
Purchase of property,
plant and equipment
|
(39,569)
|
(34,474)
|
|
(273,030)
|
(379,976)
|
Receipts of government
grants related to property, plant and equipment
|
-
|
-
|
|
-
|
67,418
|
Receipts on mature term
deposits
|
5,000,000
|
-
|
|
5,000,000
|
25,000,000
|
Purchase of term
deposits
|
(8,380,309)
|
-
|
|
(35,880,309)
|
-
|
|
(3,419,878)
|
(34,474)
|
|
(31,153,339)
|
24,687,442
|
|
|
|
|
|
|
Financing
activities
|
|
|
|
|
|
Payments made on lease
liability
|
(63,486)
|
(63,608)
|
|
(263,620)
|
(249,246)
|
Common shares
repurchased
|
(778,820)
|
(402,837)
|
|
(2,223,405)
|
(1,200,835)
|
Exercise of common
share options
|
836,199
|
1,664,006
|
|
972,431
|
1,924,361
|
|
(6,107)
|
1,197,561
|
|
(1,514,594)
|
474,280
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rate
changes on cash
|
276,921
|
23,551
|
|
145,681
|
(46,134)
|
|
|
|
|
|
|
Change in cash
during the period
|
(4,373,713)
|
1,475,554
|
|
(37,418,210)
|
25,589,655
|
|
|
|
|
|
|
Cash - Beginning of
period
|
9,182,319
|
40,751,262
|
|
42,226,816
|
16,637,161
|
|
|
|
|
|
|
Cash - End of
period
|
4,808,606
|
42,226,816
|
|
4,808,606
|
42,226,816
|
SOURCE EcoSynthetix Inc.